Walsh & Associates’s Pfizer PFE Stock Holding History

Walsh & Associates’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11	Closed	-$309	–	280
2026 Q1	$309	Buy	+11	New	+$293	﹤0.01%	250

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Walsh & Associates's PFE Position: Q2 2026 in Review

Walsh & Associates sold out of Pfizer (PFE) in Q2 2026, closing a stake of 11 shares — an estimated $309 sold.

Walsh & Associates first reported a position in PFE in Q1 2026 and held it in 1 quarter. The position peaked at $309 in Q1 2026. 2,813 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Walsh & Associates reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
Walsh & Associates sold 11 Pfizer shares in Q2 2026, an estimated $309.
Walsh & Associates first reported a position in Pfizer in Q1 2026 and held it in 1 quarter.
Walsh & Associates's Pfizer position peaked at $309 in Q1 2026.
2,813 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Walsh & Associates's 13F filing for Q2 2026, filed 21 Jul 2026.